Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16569335 | 0.91 | SMYD3 (0.39) | SMN1; SMN2HPGDKMT2AEPHX1SMYD3 | |
| SCHEMBL5596894 | 0.82 | MTNR1A (0.43) | SMN1; SMN2HPGDKMT2AEPHX1ALDH1A1 | |
| SCHEMBL9937368 | 0.81 | SMYD3 (0.43) | SMN1; SMN2HPGDKMT2AEPHX1ALDH1A1 | |
| SCHEMBL5597120 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2HPGDKMT2AALDH1A1ATM | |
| SCHEMBL991938 | 0.78 | SMN1; SMN2 (0.61) | SMN1; SMN2HPGDKMT2AEPHX1ALDH1A1 | |
| SCHEMBL31723928 | 0.78 | — | — | |
| SCHEMBL23475863 | 0.77 | EPHX1 (0.61) | SMN1; SMN2HPGDKMT2AEPHX1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3512220 | 0.77 | SMN1; SMN2 (0.59) | SMN1; SMN2HPGDKMT2AEPHX1ALDH1A1 | |
| SCHEMBL22546754 | 0.77 | EPHX1 (0.61) | SMN1; SMN2HPGDKMT2AEPHX1ALDH1A1 | |
| SCHEMBL23475876 | 0.77 | EPHX1 (0.61) | SMN1; SMN2HPGDKMT2AEPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091926-B1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | claimed |
| EP-1765789-B1 | N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | claimed |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | CHIRON CORPORATION | 2013-01-17 | — | — | US | claimed |
| US-8318791-B2 | Substituted imidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-11-27 | — | — | US | claimed |
| US-8129358-B2 | Substituted pyrazole and triazole compounds as KSP inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | claimed |
| JP-4836280-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| US-7902240-B2 | Kinesin spindle protein (KSP); anticancer agents; antiproliferative agents; e.g. N-((S)-3-amino-4-fluorobutyl)-N ((R)-1-(1-benzyl-3-(2,5-difluorophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)nicotinamide | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | claimed |
| US-20100034813-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | claimed |
| US-20090258016-A1 | Substituted imidazole derivatives | WANG WEIBO | 2009-10-15 | — | — | US | claimed |
| EP-2091926-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | Novartis AG (CH) | 2009-08-26 | — | — | EP | claimed |
| US-7576221-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2-methylpropyl]-4-methylbenzamide; kinesin-related proteins (KRP) inhibitors; anticarcinogenic agent | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-08-18 | — | — | US | claimed |
| US-20080200462-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG | 2008-08-21 | — | — | US | claimed |
| WO-2008063912-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | claimed |
| EP-1765789-A1 | N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| US-20060009472-A1 | Substituted imidazole derivatives | CHIRON CORPORATION | 2006-01-12 | — | — | US | claimed |
| WO-2006002236-A1 | N- (1- (1-BENZYL -4-PHENYL-1H-IMIDAZOL-2-YL) -2,2-DYMETHYLPROPYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-01-05 | — | — | WO | claimed |
| EP-2091926-B1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-8735599-B2 | Substituted imidazole derivates | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20060009472-A1 | Substituted imidazole derivatives | CHIRON CORPORATION | 2006-01-12 | — | — | US | disclosed |
| WO-2006002236-A1 | N- (1- (1-BENZYL -4-PHENYL-1H-IMIDAZOL-2-YL) -2,2-DYMETHYLPROPYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009472-A1 | Substituted imidazole derivatives | ABCG2, CYP2C19, AADAC | SMN1; SMN2 3720/4885HPGD 263/4885KMT2A 2589/4885 |
| US-20100034813-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | CYP3A43, ABCG2, CYP3A7 | SMN1; SMN2 4528/4885HPGD 1531/4885KMT2A 1631/4885 |
| US-20080200462-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | CYP3A43, ABCG2, CYP3A7 | SMN1; SMN2 4528/4885HPGD 1531/4885KMT2A 1631/4885 |
| US-20090258016-A1 | Substituted imidazole derivatives | ABCG2, CYP2C19, AADAC | SMN1; SMN2 3720/4885HPGD 263/4885KMT2A 2589/4885 |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | ABCG2, CYP2C19, AADAC | SMN1; SMN2 3720/4885HPGD 263/4885KMT2A 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.